Navigation Links
U.S. FDA Licenses DAPTACEL(R) Vaccine for the Fifth Consecutive Dose in the Pediatric DTaP Immunization Series

- DAPTACEL vaccine is licensed for the entire immunization series to

protect against diphtheria, tetanus, and pertussis -

SWIFTWATER, Pa. and LYON, France, March 13 /PRNewswire-FirstCall/ -- Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, announced today that the U.S. Food and Drug Administration (FDA) has licensed DAPTACEL(R) (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) to be administered as a fifth consecutive diphtheria, tetanus, and acellular pertussis (DTaP) vaccine dose for children 4 years through 6 years of age for the prevention of diphtheria, tetanus, and pertussis.

In 2002, DAPTACEL vaccine was licensed by the FDA for four consecutive doses, currently administered at 2, 4, 6, and 15 to 20 months of age. The approval of the fifth consecutive dose of DAPTACEL vaccine completes the FDA license for the entire five-dose DAPTACEL vaccine series enabling health-care professionals to administer the same brand of DTaP vaccine for the series as recommended by the Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP), the American Academy of Pediatrics (AAP), and the American Academy of Family Physicians (AAFP).

The fifth consecutive dose of DAPTACEL vaccine also provides a convenient fit with the CDC's recommended immunization schedule. According to the ACIP, AAP, and AAFP recommendations, these five doses should be administered before 7 years of age.

The safety of DAPTACEL vaccine was demonstrated in a clinical trial involving 487 children across 22 different trial sites who received DAPTACEL vaccine as a fifth consecutive dose. Out of the subjects included in the safety examination in this study, 98 percent (477/487) completed the 180-day safety follow-up after receiving the fifth dose. Of the 10 children (2 percent of 487) who did not complete the 180-day follow-up, 3 were lost to follow-up, 6 were discontinued due to non-compliance, and 1 withdrew voluntarily. None of the children involved in the study withdrew as a result of an adverse event or contraindication. Additionally, the majority of solicited local and systemic reactions occurred within 3 days of immunization and were considered to be of mild or moderate severity.

Following administration of DAPTACEL vaccine as the fifth dose, more than 93 percent of subjects experienced a booster response to each of the pertussis components. Additionally, all participants (100 percent) achieved antibody responses greater than or equal to 0.1 IU/mL for both the tetanus and diphtheria antigens, indicating that protective levels had been achieved. In assessing long-term protection, the study found that 99.6 percent (250/251) and 98.8 percent (248/251) of subjects achieved levels greater than or equal to 1.0 IU/mL for diphtheria and tetanus, respectively.

About DAPTACEL Vaccine

DAPTACEL vaccine is given to infants and children 6 weeks through 6 years (prior to 7th birthday) to prevent 3 serious diseases: diphtheria, tetanus (lockjaw), and pertussis (whooping cough). As with any vaccine, vaccination with DAPTACEL vaccine may not protect 100 percent of individuals. There are risks associated with all vaccines. The most common side effects with DAPTACEL vaccine are redness, swelling, and soreness or tenderness where the injection was given; fever, fussiness, and crying more than usual. Other side effects may occur. DAPTACEL vaccine should not be given to children who, after a previous dose of the vaccine, have had a serious allergic reaction (anaphylactic reaction) or encephalopathy not attributable to another cause.

For more information about DAPTACEL vaccine, refer to the Patient Information on and talk to your child's health-care provider.

About sanofi-aventis

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Sanofi Pasteur, the vaccines division of sanofi-aventis Group, provided more than 1.6 billion doses of vaccine in 2007, making it possible to immunize more than 500 million people across the globe. A world leader in the vaccine industry, sanofi pasteur offers the broadest range of vaccines protecting against 20 infectious diseases. The company's heritage, to create vaccines that protect life, dates back more than a century. Sanofi Pasteur is the largest company entirely dedicated to vaccines. Every day, the company invests more than EUR1 million in research and development. For more information, please visit: or

Forward Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include financial projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future events, operations, products and services, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans" and similar expressions. Although sanofi-aventis' management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of sanofi-aventis, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the public filings with the SEC and the AMF made by sanofi-aventis, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in sanofi-aventis' annual report on Form 20-F for the year ended December 31, 2007. Other than as required by applicable law, sanofi-aventis does not undertake any obligation to update or revise any forward-looking information or statements.

SOURCE sanofi-aventis
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
2. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
3. Medinet Licenses MaxCyte Cell Loading Technology for Cancer Immunotherapy in Japan
4. Codexis Licenses New Drug Metabolite Profiling and Lead Diversification Technology From the California Institute of Technology
5. Southern Research Institute Licenses Anti-Cancer Drug Compound to Virium Pharmaceuticals
6. Protherics Licenses its CoVaccine HT Adjuvant to Nobilon for Influenza Vaccine Indications
7. HUYA Bioscience International Licenses Clinical Stage Anti-Arrhythmic Compound from the Shanghai Institute of Materia Medica
8. Syngenta Licenses Chromatin Gene Stacking Technology
9. Utrecht University Licenses MetaDrug From GeneGo for Drug Innovation
10. Prometheus Licenses COLAL-PRED(R) From Alizyme
11. Maxygen Licenses Dengue Vaccine Technology to sanofi pasteur
Post Your Comments:
(Date:12/1/2015)... , Dec. 1, 2015  CardioCell LLC, ... allogeneic stem cells for cardiovascular indications, intends to ... protocol based on recommendations from a Heart Failure ... its Scientific Advisory Board members . In ... preliminary Phase IIa safety and efficacy data from ...
(Date:12/1/2015)... 1, 2015 Cepheid (Nasdaq: CPHD ) ... the Piper Jaffray Healthcare Conference in New ... is reaffirming its outlook for the fourth quarter of ... to discussing longer term business model expectations. ...  "We continue to be the fastest growing company of ...
(Date:11/30/2015)... ... November 30, 2015 , ... Global Stem Cells ... aesthetics professionals from Central America and abroad for the first Iberoamerican Convention on ... Feb. 17-19, 2016. Testart will present and discuss new trends in anti-aging stem ...
(Date:11/30/2015)... Inc. (NYSE: BIOA ), a leader in renewable materials, ... on Climate Pledge, alongside more than 140 companies from across ... to demonstrate an ongoing commitment to climate action and to ... Paris climate negotiations. Sarnia, ... . --> BioAmber uses biotechnology to convert renewable ...
Breaking Biology Technology:
(Date:11/19/2015)... , Nov. 19, 2015  Although some 350 ... is dominated by a few companies, according to Kalorama ... own 51% of the market share of the 6.1 ... The World Market for Molecular Diagnostic s . ... "The market is still controlled by one company and ...
(Date:11/18/2015)... 2015 --> ... market report titled  Gesture Recognition Market - Global Industry ... 2021. According to the report, the global gesture recognition market was valued ... reach US$29.1 bn by 2021, at a CAGR of ... America dominated the global gesture recognition market ...
(Date:11/17/2015)... 17, 2015 Paris ... --> Paris , qui s,est ... DERMALOG, le leader de l,innovation biométrique, a inventé le ... et empreintes sur la même surface de balayage. Jusqu,ici, ... l,autre pour les empreintes digitales. Désormais, un seul scanner ...
Breaking Biology News(10 mins):